Sample Report

Oncology Liquid Biopsy (LBx) Market Report 2024 - 2029

Liquid biopsies (LBx), which, to-date, have been used largely for genomic profiling and therapy selection, are finding new applications throughout the patient journey and within pharma research. To help predict the future state of the market, we have developed an evaluation framework to identify and assess areas of growth within the liquid biopsy market.

See more details below.

 

 

Complete this form to receive a copy of the sample report.

Segmentations Covered in Market Analysis:

Table of Contents:
  • Introduction & Methodology
  • Executive Summary
  • Therapy Selection
  • MRD / Monitoring
  • Early Cancer Detection
  • Biopharma Trials & Research
  • Company Profiles
  • Primary Vendor Feedback (Available as part of the Global license only)
  • Appendix
 
Updated Content:
  • Incorporated the latest trends in the LBx market, based on interviews (N = 38) with experts, a clinical EDx-focused survey (N = 207) and extensive secondary research
  • Assessed new / current offerings and expected future portfolio developments
  • Provided verbatim quotes from primary research to illustrate a variety of viewpoints and experiences
  • Updated our database of LBx companies and their offerings, evaluated the latest performance data from key players
  • Updated market sizing, segmentation, and forecast based on primary research findings and publicly-available financials
  • Evaluated emerging, high-growth applications in depth, elucidating both quantitative and qualitative market divers, moderators, and trends: (Minimal residual disease / monitoring, Early cancer detection)
  • Updated and added new deep-dive profiles of select key competitors
  • Included primary vendor feedback on perceived strengths and weaknesses, as well as stakeholder familiarity and satisfaction scores as part of the Global Report License
Updated Market Numbers:

  • Updated four market models to estimate the different segments of the LBx market; triangulated the market estimates against publicly available data(e.g., from SEC filings)
  • Informed model assumptions with primary and secondary research, as well as DeciBio domain expertise
  • Assessed market sizes for each of the market segments analyzed, including:
    • Customer type (clinical, pharma)
    • Indication
    • Application
    • Competitor
    • Geography
  • Projected revenues for each market segment from current year (2024) through 2029

Technologies and Revenues Included:

  • Liquid biopsies, in which a bodily fluid, primarily blood, is taken to detect molecular biomarkers
  • Any soluble analyte (e.g., cfDNA, cfRNA, CTCs, exosomes, methylation)
  • LBx testing done in routine clinical care and as part of biopharma trials and translational research
  • Oncology-focused applications including cancer early detection (EDx), therapy (Tx) selection, and minimum residual disease (MRD) / monitoring
  • Kits / reagents (e.g., off the shelf assays and LBx library prep) used in the testing of blood-based oncology biomarkers; the revenue captured is there venue to the kit manufacturer
  • Send-out services in which a sample is sent to a centralized testing location; the revenue captured is the revenue to the service provider

Technologies and Revenues Excluded:

  • Germline testing, prognostic testing, or any other kind of testing performed on analytes extracted from peripheral blood cells
  • Academic trials and research (i.e., non-industry sponsored)
  • Applications outside of oncology such as organ transplant, reproductive health, prenatal screening, routine bloodwork
  • Sequencing reagents used to perform the assay
  • Instruments and platforms used to run / analyze LBx samples (e.g., NGS, PCR machines)
  • Software or bioinformatics support used in the analysis of LBx assays
  • CDx licensing and development deals revenue, even if the licensing / deal involved LBx

©2024 DeciBio. All rights reserved.